← Back to all trials
Active Not Recruiting
NCT05743881
A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months
Conditions: Respiratory Syncytial Virus, Human Metapneumovirus
Sex: All
Ages: 5 Months – 24 Months
Healthy volunteers: No
Phase: PHASE1
Enrollment: 186
Sponsor: ModernaTX, Inc.
Location: Matrix Clinical Research Los Angeles California
Summary
The purpose of this study is to assess the safety and immunogenicity of mRNA-1365, an mRNA vaccine targeting respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) and mRNA-1345, an mRNA vaccine targeting RSV, in participants aged 5 months to \
Eligibility Criteria
Inclusion Criteria:
* The participant is 8 months to \
Source: ClinicalTrials.gov (NCT05743881). StuddyBuddy aggregates publicly available trial information.
